Paradigm Biopharmaceuticals Ltd. · ASX:PAR
Paradigm Biopharmaceuticals — Bell Potter Healthcare Conference 2021
16 slides from Paradigm Biopharmaceuticals's conference presentation, Nov 9, 2021
Slide 1: Paradigm Presentation at the Bell Potter Healthcare Conference
ASX RELEASE 9th November 2021 Paradigm Presentation at the Bell Potter Healthcare Conference For personal use only Paradigm Biopharmaceuticals Ltd (ASX: PAR) (“Paradigm” or “the Company”), a clinical stage biopharmaceutical company focussed on repurposing existing molecules for new indications with
Slide 2: Bell Potter Healthcare Conference
For personal use only BELL POTTER HEALTHCARE CONFERENCE
Slide 3: Disclaimer
Paradigm Biopharma 03/08/21 2 Disclaimer For personal use only This document, together with any information communicated by Paradigm Biopharmaceuticals Ltd ASX:PAR (known as “Paradigm”, “Paradigm Biopharma” or “the Company”), in any presentation or discussion relating to this document (collectively,
Slide 4: Executive Summary
Paradigm Biopharma 03/08/21 3 Executive For personal use only Lead program: Commercial: Summary Phase 3 global study in Knee OA. Blockbuster potential with 32m+ sufferers in the US alone Global Market Research confirmed US$2500 achievable for Zilosul® for indication of pain and function in knee OA.
Slide 5: Global Harmonised Pivotal Trial – PARA_OA_002
Paradigm Biopharma 03/08/21 4 Phase 3 Company For personal use only Global Harmonised Pivotal Trial – PARA_OA_002 United States Australia Europe and UK • FDA clears IND application investigating • Eight (8) sites have been selected. • Twelve (12) sites to be initiated Pentosan Polysulphate Sodium (P
Slide 6: Phase 3 Trial Design
Paradigm Biopharma 03/08/21 5 Phase 3 Trial Design For personal use only Trial Design 1 STAGE 2 STAGE Treatment Period Follow-Up Period Treatment Period Follow-Up Period 2 x weekly dose (N=117) Selected PPS Dose Regimen (N=235) Weekly dose (N=117) Screening Screening Weekly Fixed Dose (N=117) Observ
Slide 7: Blockbuster market opportunity
Paradigm Biopharma 03/08/21 6 72 Blockbuster For personal use only Total prevalence of OA in key markets Knee and Hip market opportunity M+ and growing 69 % Zilosul® aims to meet a OA patients dissatisfied with current significant unmet need treatments1 in osteoarthritis USA CAN EU5 AUS 81 Target up
Slide 8: Global Market Research
7 Paradigm Biopharma 03/08/21 7 Global Market Research For personal use only › In 2021 Paradigm conducted market research in major global markets, with physicians, funding decision makers (payers) and patients to better understand willingness-to-pay and willingness-to-prescribe Zilosul for osteoarth
Slide 9: Zilosul's proposed profile
8 Paradigm Biopharma 03/08/21 8 Zilosul’s proposed profile For personal use only Assuming sustained efficacy and robust safety data, physicians and was regarded positively payers believe Zilosul® will provide high value to the treatment of kOA by covering some important unmet needs Meaningful pain r
Slide 10: Zilosul in pain and function treatment algorithm
9 Paradigm Biopharma 03/08/21 9 Pain & function For personal use only NSAIDS / Cox-2 1L Physicians 2L Dual-acting opioid (tramadol) IA injection – CS (e.g. triamcinolone) may consider Pain 2L Persists Zilosul® as a IA injection – HA ZILOSUL P&F second line Pain Persists therapy 3L Opioid Opioid anal
Slide 11: Zilosul in disease modification treatment algorithm
10 Paradigm Biopharma 03/08/21 10 Disease For personal use only modification 1L NSAIDS / Cox-2 ZILOSUL DM Zilosul® may be used early Dual-acting opioid IA injection – CS 2L (tramadol) Pain (e.g. triamcinolone) in therapy 2L Persists IA injection – HA Pain Persists 3L Opioid analgesics Opioid (acetam
Slide 12: Target pricing
Paradigm Biopharma 03/08/21 11 Target pricing For personal use only Pricing potential of Zilosul in P&F and DM compared to price benchmark Price points for comparators Weak opioids CS IA HA IA Achievable for 8000 P&F and 7000 $6K+ Achievable price range (USD year) a significantly 6000 higher price f
Slide 13: DMOAD
Paradigm Biopharma 03/08/21 12 DMOAD For personal use only Current programs to inform of Zilosul® potential as a DMOAD PARA_OA_008 - Australia Canine OA Study • Biomarker study assessing change from • Dogs with OA of the stifle joint are treated with PPS at a baseline in multiple objective measures
Slide 14: MPS clinical programs in Orphan designation
For personal use only Paradigm Biopharma 03/08/21 13 MPS MPS I - Australia MPS VI - Brazil Clinical programs • Open label trial currently enrolling up to 10 • A double-blind placebo-controlled trial with 12 in Orphan subjects. Dosed weekly for 12 weeks then subjects. Dosed weekly for 24-weeks. every
Slide 15: R&D Pipeline
Paradigm Biopharma 03/08/21 14 R&D Pipeline For personal use only Repurposing of PPS across several acute and chronic medical indications. Indication / Action of PPS Stage of Development Status Alphavirus induced arthralgia • Anti-inflammatory target: NF-kB • Preclinical Proof-of concept for CHIK-V:
Slide 16: For more information please visit
For personal use only Paradigm Biopharma 03/08/21 15 For more information please visit: paradigmbiopharma.com or email any queries to investorrelations@paradigmbiopharma.com
Paradigm Biopharmaceuticals — Bell Potter Healthcare Conference 2021 on 6ix